The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis

Vaccine

Volumn 13, Issue 16, 1995, Pages 1501-1508

  Idänpään Heikkilä, Ilona ^a   Muttilainen, Susanna ^a   Wahlström, Eva ^a   Saarinen, Leena ^a   Leinonen, Maija ^a   Sarvas, Matti ^a   Helena Makela P ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

class 1 protein; liposome vaccine; Neisseria meningitidis

Indexed keywords

LIPOSOME; OUTER MEMBRANE PROTEIN; PHOSPHATIDYLCHOLINE; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BACILLUS SUBTILIS; CONTROLLED STUDY; ENZYME IMMUNOASSAY; GUINEA PIG; MENINGITIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMAL; ANTIBODIES, BACTERIAL; BACILLUS SUBTILIS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; FEASIBILITY STUDIES; FEMALE; GUINEA PIGS; INDIVIDUALITY; LIPOSOMES; MICE; MICE, INBRED STRAINS; NEISSERIA MENINGITIDIS; RABBITS; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; VACCINES, SYNTHETIC;

EID: 0028791267     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00101-6     Document Type: Article

References (39)

1. Immunologic response of man to group B meningococcal polysaccharide vaccines
2. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man
3. Vaccines for prevention of meningococcal disease
4. Antigenic similarities between brain components and bacteria causing meningitidis. Implications for vaccine development and pathogenesis
5. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile
6. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba
7. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
8. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paolo, Brazil
9. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay
10. Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer membrane protein
11. Variability of low-molecular-weight, heat-modifiable outer membrane proteins of Neisseria meningitidis
12. The class 1 outer membrane protein of Neisseria meningitidis produced in Bacillus subtilis can give rise to protective immunity
13. The Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes
14. The class 1 outer membrane protein of Neisseria meningitidis: gene sequence and structural and immunological similarities to gonococcal porins
15. Five structural classes of major outer membrane proteins in Neisseria meningitidis
16. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.7,16 in infant rat infection model: new prospects for vaccine development
17. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide
18. IgG subclasses—a review
19. Localization of the binding site for the human high-affinity Fc receptor on IgG
20. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity
21. Monoclonal antibodies to the R-type lipopolysaccharide of Neisseria meningitidis protect infant rats from meningococcal infection
22. Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA
23. Immunological adjuvants: a role for liposomes
24. Liposomes as carriers of antigens and adjuvants
25. Liposomes as immunological adjuvants
26. The role of macrophages in the immunoadjuvant action of liposomes: effects of elimination of splenic macrophages on the immune reponse against intravenously injected liposome associated albumin antigen
27. The macrophage as the principal antigen presenting cell for liposome encapsulated antigens
28. Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A
29. The carrier potential of liposomes in biology and medicine
30. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy
31. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks
32. Effective subunit vaccines against an enveloped animal virus
33. Characterization and specificity of antibodies to protein I Neisseria gonorrhoeae produced by injection with various protein I-adjuvant preparations
34. Gonococcal porin vaccine evaluation: comparison of por proteosomes, liposomes, and blebs isolated from rmp deletion mutants
35. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein